PBU The Pension Fund of Early Childhood & Youth Educators grew its position in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 6.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 82,349 shares of the medical instruments supplier’s stock after acquiring an additional 4,958 shares during the quarter. PBU The Pension Fund of Early Childhood & Youth Educators’ holdings in Becton, Dickinson and Company were worth $14,740,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. bought a new stake in Becton, Dickinson and Company in the 2nd quarter worth about $3,721,533,000. Bank of America Corp DE bought a new position in shares of Becton, Dickinson and Company during the 2nd quarter worth approximately $474,993,000. First Eagle Investment Management LLC grew its holdings in shares of Becton, Dickinson and Company by 15.8% in the second quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier’s stock valued at $2,090,675,000 after acquiring an additional 1,887,224 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Becton, Dickinson and Company during the second quarter valued at approximately $247,372,000. Finally, Deutsche Bank AG purchased a new stake in shares of Becton, Dickinson and Company during the second quarter valued at approximately $204,226,000. Institutional investors own 86.97% of the company’s stock.
Analyst Upgrades and Downgrades
BDX has been the subject of several research analyst reports. Wolfe Research began coverage on Becton, Dickinson and Company in a research report on Tuesday, October 20th. They set an “outperform” rating for the company. JPMorgan Chase & Co. boosted their price target on shares of Becton, Dickinson and Company from $170.00 to $202.00 and gave the stock a “neutral” rating in a report on Friday, November 6th. Royal Bank Of Canada increased their price target on shares of Becton, Dickinson and Company from $190.00 to $225.00 and gave the company a “sector perform” rating in a research report on Friday, November 6th. Jefferies Financial Group restated a “buy” rating and set a $242.00 price objective on shares of Becton, Dickinson and Company in a report on Thursday, November 5th. Finally, Barclays lifted their price objective on shares of Becton, Dickinson and Company from $165.00 to $195.00 and gave the stock an “underweight” rating in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $197.47.
View Our Latest Research Report on Becton, Dickinson and Company
Becton, Dickinson and Company Trading Up 0.6%
Shares of BDX stock opened at $215.72 on Friday. The stock has a market capitalization of $59.44 billion, a price-to-earnings ratio of 52.11, a PEG ratio of 3.59 and a beta of 0.22. The company’s fifty day simple moving average is $190.29 and its two-hundred day simple moving average is $170.48. Becton, Dickinson and Company has a 1 year low of $140.11 and a 1 year high of $216.85. The company has a debt-to-equity ratio of 0.54, a current ratio of 0.87 and a quick ratio of 0.54.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last posted its earnings results on Thursday, November 5th. The medical instruments supplier reported $4.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.07 by $0.08. The business had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.11 billion. Becton, Dickinson and Company had a return on equity of 14.90% and a net margin of 5.66%. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.96 EPS. As a group, analysts anticipate that Becton, Dickinson and Company will post 13.21 earnings per share for the current year.
Becton, Dickinson and Company Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, December 31st. Investors of record on Thursday, December 10th will be given a $1.06 dividend. This represents a $4.24 annualized dividend and a yield of 2.0%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. The ex-dividend date is Thursday, December 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 101.45%.
Becton, Dickinson and Company declared that its Board of Directors has initiated a share buyback plan on Thursday, November 5th that authorizes the company to buy back 10,000,000 shares. This buyback authorization authorizes the medical instruments supplier to purchase up to 3.6% of its shares through open market purchases. Share buyback plans are often a sign that the company’s management believes its shares are undervalued.
Insiders Place Their Bets
In other news, CEO Thomas E. Polen, Jr. sold 2,993 shares of the stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $210.00, for a total transaction of $628,530.00. Following the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $23,134,230. This represents a 2.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the transaction, the executive vice president directly owned 19,720 shares in the company, valued at approximately $3,717,022.80. This represents a 0.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 3,310 shares of company stock worth $688,650. 0.40% of the stock is owned by insiders.
Becton, Dickinson and Company Company Profile
Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies. BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.
Recommended Stories
- Five stocks we like better than Becton, Dickinson and Company
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
